Top News

Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop PD-L1 Inhibitor Program for Patients with Serious Blood Cancers

Business Wire, 24.04.2015

Celgene International II Sārl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that it has entered into a strategic collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC, to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies. Approximately 1.75 million patients globally suffer from blood cancer and many are in need of new treatment options.

more

Next Event

 

Community Login







Bachem Holding AG

loroch.ch

 Wissenschaft im Gespraech | Den Naturwissenschaften fehlt der Nachwuchs | Schweizer Radio DRS

The potential in the land

LRC TriCEPS™ technology

BBC - End of Drug Discovery